Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
REGULATORY
Kitasato Daiichi Sankyo Vaccine to Remain in State Vaccine Project
A health ministry committee agreed on March 20 that Kitasato Daiichi Sankyo Vaccine will continue the cell culture-based vaccine production project for new strains of influenza. Kitasato Daiichi Sankyo Vaccine was selected to build a cell culture-based vaccine supply system…
To read the full story
REGULATORY
- Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch
December 11, 2025
- Two Bayer/AskBio Gene Therapies Bag Sakigake Designation
December 11, 2025
- Truqap Braced for Price Cut after Cost-Effectiveness Assessment
December 11, 2025
- LDP Lawmakers’ League Urges Continued Coverage for Local Transdermal Analgesics
December 10, 2025
- Senior LDP Lawmakers Call for “Net Plus” in FY2026 Fee, Drug Price Revisions
December 10, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…